• Product NameRecombinant Human B-Cell Maturation Antigen/TNFRSF17
• Host SpeciesEscherichia coli.
• Purification> 98 % by SDS-PAGE and HPLC analyses.
• Biological ActivityFully biologically active when compared to standard. The ED50 as determined by its ability to inhibit APRIL-mediated proliferation of anti-IgM stimulated murine B cells is no less than 40 ng/ml, corresponding to a specific activity of > 2.5 x10⁴ IU/mg in the presence of 100 ng/ml human APRIL.
• EndotoxinLess than 1 EU/ug of rHuBCMA as determined by LAL method.
• Alternative Names    TNFRSF17, BCM, CD269
• UniprotQ02223
• Gene ID608
• Calculated MW Approximately 5.4 kDa, a single non-glycosylated polypeptide chain containing 50 amino acids.
• Target Sequence AGQCSQNEYF DSLLHACIPC QLRCSSNTPP LTCQRYCNAS VTNSVKGTNA
• Formulation Lyophilized from a 0.2 μm filtered concentrated solution in 30 % acetonitrile, 0.1 % TFA.
• Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 ˚C as supplied.- 1 month, 2 to 8 ˚C under sterile conditions after reconstitution.- 3 months, -20 to -70 ˚C under sterile conditions after reconstitution.

B-Cell Maturation Antigen (BCMA), encoded by the TNFRSF17 gene in humans. It is a member of the TNF receptor superfamily and a type III membrane protein containing one extracellular cysteine rich domain. It is expressed on mature B-cells and other B-cell lines. BCMA can binds to TNFSF13B/BLyS/BAFF and TNFSF13/APRIL, and has functions that promotes B-cell survival, plays a role in the regulation of humoral immunity, and activates NF-kappa-B and JNK BCMA.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting